FBP1 is increasingly identified as a tumor suppressor as loss of FBP1 expression has been shown to promote tumor progression by enhancing aerobic glycolysis, thereby resulting in poor prognosis in patients with clear cell renal cell carcinoma, breast cancer and hepatocellular carcinoma [13–16]. This evidence concerns the gene FBP1 and breast carcinoma.